Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD)

References

• Hassan K, Bhalla V, Ezz El Regal M, et al. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014 Sep 14;20(34):12082–12101.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.
   PubMed Web of Science ®Google Scholar
• A-Kader HH. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J Pediatr. 2009;5(4):245–254.
   PubMed Web of Science ®Google Scholar
• Boldrini R, Devito R, Biselli R, et al. Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathol Res Pract. 2004;200:231–240.
   PubMed Web of Science ®Google Scholar
• Grabowski, G.A., Charnas, L., Du, H. Lysosomal acid lipase deficiencies: the Wolman disease/cholesteryl ester storage disease spectrum. in: D. Scriver Valle, A.L. Beaudet, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio (Eds.) Metabolic and molecular bases of inherited disease – OMMBID. 8th ed. McGraw-Hill, New York; 2012
   Google Scholar
• Pagani F, Pariyarath R, Garcia R, et al. New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J Lipid Res. 1998;39:1382–1388.
   PubMed Web of Science ®Google Scholar
• Jones SA, Bernstein DL, Bialer MG, et al. Severe and rapid disease course in the natural history of infants with lysosomal acid lipase deficiency. Mol Genet Metab. 2014;111:S57–S58.
   Web of Science ®Google Scholar
• Assmann G, Seedorf U. Prevalence of cholesteryl ester storage disease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. New York (NY): McGraw Hill; 2001. p. 3551–3572.
   Google Scholar
• Grabowski GA, Charnas L, Du H. 2012. Lysosomal acid lipase deficiencies: the Wolman disease/cholesteryl ester storage disease spectrum. In: Scriver Valle D, Beaudet AL, Vogelstein B, et al., editors. Metabolic and molecular bases of inherited disease – OMMBID. New York (NY): McGraw-Hill. Available from: www.ommbid.com
   Google Scholar
• Hůlková H, Elleder M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology. 2012;60:1107–1113.
   PubMed Web of Science ®Google Scholar
• Sloan HR, Fredrickson DS. Enzyme deficiency in cholesteryl ester storage disease. J Clin Invest. 1972;51(7):1923–1926.
   PubMed Web of Science ®Google Scholar
• Sloan HR, Fredrickson DS. Rare familial diseases with neutral lipid storage. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The metabolic basis of inherited disease. New York (NY): McGraw Hill; 1972. p. 808.
   Google Scholar
• Burke JA, Schubert W. Deficient activity of hepatic acid lipase in cholesterol ester storage disease. Science. 1972;176(4032):309–310.
   PubMed Web of Science ®Google Scholar
• Aslanidis C, Ries S, Fehringer P, et al. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 1996;33:85–93.
   PubMed Web of Science ®Google Scholar
• Shteyer E, Villenchik R, Mahamid M, et al. Low serum lysosomal acid lipase activity correlates with advanced liver disease. Int J Mol. 2016 Mar;17(3):312.
   Web of Science ®Google Scholar
• Selvakumar PKC, Kabbany MN, Lopez R, et al. Reduced lysosomal acid lipase activity - a potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Dig Liver Dis Dig. 2016;48(8):909–913.
   PubMed Web of Science ®Google Scholar
• Abramov A, Schorr S, Wolman M. Generalized xanthomatosis with calcified adrenals. Am J Dis Child. 1956;91:282–286.
   PubMedGoogle Scholar
• Fredrickson DS. Newly recognized disorders of cholesterol metabolism. Ann Intern Med. 1963;58:718.
   Web of Science ®Google Scholar
• Reynolds T. Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. J Clin Pathol. 2013;66:918–923.
   PubMed Web of Science ®Google Scholar
• Saito S, Ohno K, Suzuki T, et al. Structural bases of Wolman disease and cholesteryl ester storage disease. Mol Genet Metab. 2012;105:244–248.
   PubMed Web of Science ®Google Scholar
• Lohse P, Maas S, Elleder M, et al. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res. 2000;41:23–31.
   PubMed Web of Science ®Google Scholar
• Scott SA, Liu B, Nazarenko I, et al. Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups. Hepatology. 2013;58:958–965.
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2013;33:2909–2914.
   PubMed Web of Science ®Google Scholar
• Valles-Ayoub Y, Esfandiarifard S, No D, et al. Wolman disease (LIPA p.G87V) genotype frequency in people of Iranian-Jewish ancestry. Genet Test Mol Biomarkers. 2011;15:395–398.
   PubMed Web of Science ®Google Scholar
• Muntoni S, Wiebusch H, Jansen-Rust M, et al. Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations. Nutr Metab Cardiovasc Dis. 2013;23:732–736.
   PubMed Web of Science ®Google Scholar
• Keller E, Kunnert B, Braun W. Cholesterol-ester storage disease of the liver in childhood. Dtsch Z Verdau Stoffwechselkr. 1977;37:231–236.
   PubMedGoogle Scholar
• Kelly DR, Hoeg JM, Demosky SJ Jr, et al. Characterization of plasma lipids and lipoproteins in cholesteryl ester storage disease. Biochem Med. 1985;33:29–37.
   PubMed Web of Science ®Google Scholar
• D’Agostino D, Bay L, Gallo G, et al. Cholesterol ester storage disease: clinical, biochemical, and pathological studies of four new cases. J Pediatr Gastroenterol Nutr. 1988;7:446–450.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Ishak KG, Rabin L, et al. Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin. Hepatology. 1990;11:764–772.
   PubMed Web of Science ®Google Scholar
• Hoeg JM, Demosky SJ Jr, Pescovitz OH, et al. Cholesteryl ester storage disease and Wolman disease: phenotypic variants of lysosomal acid cholesteryl ester hydrolase deficiency. Am J Human Genet. 1984;36:1190–1203.
   PubMed Web of Science ®Google Scholar
• Hill SC, Hoeg JM, Dwyer AJ, et al. CT findings in acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. J Comput Assist Tomogr. 1983;7:815–818.
   PubMed Web of Science ®Google Scholar
• Van Erum S, Gnat D, Finne C, et al. Cholesteryl ester storage disease with secondary lecithin cholesterol acyl transferase deficiency. J Inherit Metab Dis. 1988;11:146–148.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Dana SE, Faust JR, et al. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem. 1975;250:8487–8495.
   PubMed Web of Science ®Google Scholar
• Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 2012;23:65–72.
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–1131.
   PubMed Web of Science ®Google Scholar
• Cummings MH, Watts GF. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin Chem. 1995;41:111–114.
   PubMed Web of Science ®Google Scholar
• Fouchier SW, Defesche JC. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr Opin Lipidol. 2013;24:332–338.
   PubMed Web of Science ®Google Scholar
• Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev. 2005;85:1343–1372.
   PubMed Web of Science ®Google Scholar
• Boadu E, Bilbey NJ, Francis GA. Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation. Curr Opin Lipidol. 2008;19:270–276.
   PubMed Web of Science ®Google Scholar
• Bowden KL, Bilbey NJ, Bilawchuk LM, et al. Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease. J Biol Chem. 2011;286:30624–30635.
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324(21):1464–1470.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Sando GN. Cloning and expression of cDNA encoding human lysosomal acid lipase/cholesteryl ester hydrolase: similarities to gastric and lingual lipases. J Biol Chem. 1991;266(33):22479–22484.
   PubMed Web of Science ®Google Scholar
• Burke JA, Schubert WK. Deficient activity of acid lipase in cholesterol ester storage disease. J Lab Clin Med. 1971;78(6):988–989.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Bryson GM, Parks JS. Lysosomal acid lipase mutations that determine phenotype in Wolman and cholesterol ester storage disease. Mol Genet Metab. 1999;68(3):333–345.
   PubMed Web of Science ®Google Scholar
• Himes RW, Barlow SE, Bove K, et al. Lysosomal acid lipase deficiency unmasked in two children with nonalcoholic fatty liver disease. Pediatrics. 2016 Oct;138(4):e20160214.
   PubMed Web of Science ®Google Scholar
• Porto AF. Lysosomal acid lipase deficiency: diagnosis and treatment of Wolman and cholesteryl ester storage diseases. Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:125–132.
   PubMed Web of Science ®Google Scholar
• Beaudet AL, Ferry GD, Nichols BL Jr, et al. Cholesterol ester storage disease: clinical, biochemical, and pathological studies. J Pediatr. 1977;90:910–914.
   PubMed Web of Science ®Google Scholar
• Haller W, Sharif K, Millar AJ, et al. Gallbladder dysfunction in cholesterol ester storage disease. J Pediatr Gastroenterol Nutr. 2010;50:555–558.
   PubMed Web of Science ®Google Scholar
• Dincsoy HP, Rolfes DB, McGraw CA, et al. Cholesterol ester storage disease and mesenteric lipodystrophy. Am J Clin Pathol. 1984;81:263–269.
   PubMed Web of Science ®Google Scholar
• Cagle PT, Ferry GD, Beaudet AL, et al. Pulmonary hypertension in an 18-year-old girl with cholesteryl ester storage disease (CESD). Am J Med Genet. 1986 Aug;24(4):711–722.
   PubMed Web of Science ®Google Scholar
• Pisciotta L, Fresa R, Bellocchio A, et al. Cholesteryl ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab. 2009;97:143–148.
   PubMed Web of Science ®Google Scholar
• Decarlis S, Agostoni C, Ferrante F, et al. Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. J Inherit Metab Dis. 2009;32(Suppl. 1):S11–S13.
   PubMed Web of Science ®Google Scholar
• Maslen CL, Babcock D, Illingworth DR. Occurrence of a mutation associated with Wolman disease in a family with cholesteryl ester storage disease. J Inherit Metab Dis. 1995;18:620–623.
   PubMed Web of Science ®Google Scholar
• Wallis K, Gross M, Kohn R, et al. A case of Wolman’s disease. Helv Paediatr Acta. 1971;26:98–111.
   PubMedGoogle Scholar
• Kyriakides EC, Filippone N, Paul B, et al. Lipid studies in Wolman’s disease. Pediatrics. 1970;46:431–436.
   PubMed Web of Science ®Google Scholar
• Marshall WC, Ockenden BG, Fosbrooke AS, et al. Wolman’s disease. A rare lipidosis with adrenal calcification. Arch Dis Child. 1969;44:331–341.
   PubMed Web of Science ®Google Scholar
• Kostner GM, Hadorn B, Roscher A, et al. Plasma lipids and lipoproteins of a patient with cholesteryl ester storage disease. J Inherit Metab Dis. 1985;8:9–12.
   PubMed Web of Science ®Google Scholar
• Gaddi A, Cicero AF, Odoo FO, et al. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3:877–886.
   PubMedGoogle Scholar
• Van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation. 2011;123:1167–1173.
   PubMed Web of Science ®Google Scholar
• Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818.
   PubMed Web of Science ®Google Scholar
• Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial combined hyperlipidemia in childhood. J Pediatr. 1990;116:514–519.
   PubMed Web of Science ®Google Scholar
• Guardamagna O, Restagno G, Rolfo E, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr. 2009;155:199–204.
   PubMed Web of Science ®Google Scholar
• The Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339–344.
   PubMed Web of Science ®Google Scholar
• The IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. Plos Genet. 2011;7:e1002260.
   PubMed Web of Science ®Google Scholar
• Wild PS, Zeller T, Schillert A, et al. A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet. 2011;4:403–412.
   PubMed Web of Science ®Google Scholar
• Burton BK, Balwani M, Feillet F, et al. A Phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373(11):1010–1020.
   PubMed Web of Science ®Google Scholar
• Burton BK, Deegan PB, Enns GM, et al. Clinical features of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr. 2015;61(6):619–625.
   PubMed Web of Science ®Google Scholar
• Elleder M, Ledvinová J, Cieslar P, et al. Subclinical course of cholesterol ester storage disease (CESD) diagnosed in adulthood. Report on two cases with remarks on the nature of the liver storage process. Virchows Arch A Pathol Anat Histopathol. 1990;416:357–365.
   PubMedGoogle Scholar
• Klima H, Ullrich K, Aslanidis C, et al. A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. J Clin Invest. 1993;92:2713–2718.
   PubMed Web of Science ®Google Scholar
• Jones SA, Valayannopoulos V, Schneider E, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016;18(5):452–458.
   PubMed Web of Science ®Google Scholar
• Hamilton J, Jones I, Srivastava R, et al. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2012;413:1207–1210.
   PubMed Web of Science ®Google Scholar
• Mukherjee M. Human digestive and metabolic lipases − a brief review. J Mol Catal B Enzym. 2003;22:369–376.
   Web of Science ®Google Scholar
• Rosenbaum AI, Cosner CC, Mariani CJ, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann−Pick type C disease therapeutics. J Med Chem. 2010;53:5281–5289.
   PubMed Web of Science ®Google Scholar
• Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495–500.
   PubMed Web of Science ®Google Scholar
• Thelwall PE, Smith FE, Leavitt MC, et al. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. J Hepatol. 2013;59:543–549.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardio. 2013;10:453–464.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, McNamara DJ, Granstrom P, et al. Lovastatin therapy for cholesterol ester storage disease in two sisters. J Pediatr. 1991;118:131–135.
   PubMed Web of Science ®Google Scholar
• Tadiboyina V, Liu DM, Miskie BA, et al. Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis. 2005;4:26.
   PubMedGoogle Scholar
• Yokoyama S, McCoy E. Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin. J Inherit Metab Dis. 1992;15:291–292.
   PubMed Web of Science ®Google Scholar
• McCoy E, Yokoyama S. Treatment of cholesteryl ester storage disease with combined cholestyramine and lovastatin. Ann N Y Acad Sci. 1991;623:453–454.
   PubMed Web of Science ®Google Scholar
• Leone L, Ippoliti PF, Antonicelli R. Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. J Pediatr. 1991;119:1008–1009.
   PubMed Web of Science ®Google Scholar
• Levy R, Ostlund RE Jr, Schonfeld G, et al. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. J Lipid Res. 1992;33:1005–1015.
   PubMed Web of Science ®Google Scholar
• Abello P, Guardamagna O, Baracco V, et al. The treatment of colesteryl storage disease (CESD) by ezetimibe monotherapy. Atheroscler Suppl. 2010;11:28.
   Web of Science ®Google Scholar
• Xu M, Liu K, Swaroop M, et al. δ-Tocopherol reduces lipid accumulation in Niemann−Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem. 2012;287:39349–39360.
   PubMed Web of Science ®Google Scholar
• Du H, Schiave S, Levine M, et al. Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet. 2001;10(16):1639–1648.
   PubMed Web of Science ®Google Scholar
• Du H, Levine M, Ganesa C, et al. The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am J Hum Genet. 2005;77(6):1061–1074.
   PubMed Web of Science ®Google Scholar
• Du H, Heur M, Witte DP, et al. Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum Gene Ther. 2002;13(11):1361–1372.
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Therapy for lysosomal acid lipase deficiency: replacing a missing link. Hepatology. 2013;58:850–852.
   PubMed Web of Science ®Google Scholar
• Stahl PD, Rodman JS, Miller MJ, et al. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci U S A. 1978;75(3):1399–1403.
   PubMed Web of Science ®Google Scholar
• Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013;58(3):950–957.
   PubMed Web of Science ®Google Scholar
• Su K, Donaldson E, Sharma R. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa. Appl Clin Genet. 2016;9:157–167.
   PubMedGoogle Scholar
• Valayannopoulos V, Plantaz D, Vara R, et al. Clinical effect of sebelipase alfa on survival and growth in infants with lysosomal acid lipase deficiency (Wolman disease). Mol Genet Metab. 2014 Feb;111(2):S108.
   Web of Science ®Google Scholar
• Goodman Z, Burton B, Alaparthi L, et al. Change in liver fibrosis in children and adults with lysosomal acid lipase deficiency after 52 weeks of sebelipase alfa (ARISE trial). Poster presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting; Nov 11; Boston. Abstract 561.
   Google Scholar
• Furuya KN, Marulkar S, Friedman M, et al. Long-term benefit of sebelipase alfa over 76 weeks in children and adults with lysosomal acid lipase deficiency (ARISE trial). Poster presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting; Nov 11; Boston. Abstract 564.
   Google Scholar
• European Medicines Agency. Kanuma product information. London: European Medicines Agency; [ cited 2015 Dec 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004004/WC500192715.pdf
   Google Scholar
• Harmatz P. Enzyme replacement therapies and immunogenicity in lysosomal storage diseases: is there a pattern? Clin Ther. 2015;37(9):2130–2134.
   PubMed Web of Science ®Google Scholar
• Jameson E, Jones S, Wraith JE. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2013;11:CD009354.
   Google Scholar
• Jones S, Plantaz D, Vara R, et al. Impact of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency. J Hepatol. 2015;62(Suppl 2):S81.
   Google Scholar
• Jyonouchi H, Cyong J-C, Shen F-W, et al. Alteration of murine serum lipase activity after allogeneic bone marrow transplantation. Clin Immunol Immunopathol. 1982;22(1):94–104.
   PubMedGoogle Scholar
• Tolar J, Petryk A, Khan K, et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant. 2009;43:21–27.
   PubMed Web of Science ®Google Scholar
• Stein J, Garty BZ, Dror Y, et al. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr. 2007;166:663–666.
   PubMed Web of Science ®Google Scholar
• Gramatges MM, Dvorak CC, Regula DP, et al. Pathological evidence of Wolman’s disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant. 2009;44:449–450.
   PubMed Web of Science ®Google Scholar
• Yanir A, Allatif MA, Weintraub M, et al. Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complications. Mol Genet Metab. 2013;109:224–226.
   PubMed Web of Science ®Google Scholar
• Ferry GD, Whisennand HH, Finegold MJ, et al. Liver transplantation for cholesteryl ester storage disease. J Pediatr Gastroenterol Nutr. 1991;12:376–378.
   PubMed Web of Science ®Google Scholar
• Kale AS, Ferry GD, Hawkins EP. End-stage renal disease in a patient with cholesteryl ester storage disease following successful liver transplantation and cyclosporine immunosuppression. J Pediatr Gastroenterol Nutr. 1995;20:95–97.
   PubMed Web of Science ®Google Scholar
• Michels VV, Driscoll DJ, Ferry GD, et al. Pulmonary vascular obstruction associated with cholesteryl ester storage disease. J Pediatr. 1979 Apr;94(4):621–623.
   PubMed Web of Science ®Google Scholar
• Arterburn JN, Lee WM, Wood RP, et al. Orthotopic liver transplantation for cholesterol ester storage disease. J Clin Gastroenterol. 1991;13(4):482–485.
   PubMed Web of Science ®Google Scholar
• Leone L, Ippoliti PF, Antonicelli R, et al. Treatment and liver transplantation for cholesterol ester storage disease. J Pediatr. 1995;127:509–510.
   PubMed Web of Science ®Google Scholar
• Elleder M, Chlumska A, Hyánek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepatol. 2000;32:528–534.
   PubMed Web of Science ®Google Scholar
• Riva S, Spada M, Sciveres M, et al. Hepatocarcinoma in a child with cholesterol ester storage disease. Dig Liver Dis. 2008;40:784.
   PubMedGoogle Scholar
• Ambler GK, Hoare M, Brais B, et al. Orthotopic liver transplantation in an adult with cholesterol ester storage disease. JIMD Rep. 2013;8:41–46.
   PubMedGoogle Scholar
• Perez Rodriguez-Cuesta JM, Suarez Tomas JI, Suarez Menendez ME, et al. Cholesterol ester storage disease in two siblings. An Esp Pediatr. 1990;32:249–252.
   PubMedGoogle Scholar
• Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850.
   PubMed Web of Science ®Google Scholar
• Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol. 2002;16:733–747.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.
   PubMed Web of Science ®Google Scholar
• Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593–1602.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164:2169–2175.
   PubMedGoogle Scholar
• Farrell GC, Wong VW, Chitturi S. NAFLD in Asia–as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307–318.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117.
   PubMed Web of Science ®Google Scholar
• Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation. 2000;69:2410–2415.
   PubMed Web of Science ®Google Scholar
• Hilden M, Christoffersen P, Juhl E, et al. Liver histology in a ‘normal’ population—examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol. 1977;12:593–597.
   PubMed Web of Science ®Google Scholar
• Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594–598.
   PubMed Web of Science ®Google Scholar
• Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002;12:49–51.
   PubMed Web of Science ®Google Scholar
• Wei JL, Leung JCF, Loong TCW, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110:1306–1314.
   PubMed Web of Science ®Google Scholar
• Salmon PA, Reedyk L. Fatty metamorphosis in patients with jejunoileal bypass. Surg Gynecol Obstet. 1975;141:75–84.
   PubMedGoogle Scholar
• Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–226.
   PubMed Web of Science ®Google Scholar
• Padilla H, Sanchez A, Powell RN, et al. Plasma amino acids in children from Guadalajara with kwashiorkor. Am J Clin Nutr. 1971;24(3):353–357.
   PubMed Web of Science ®Google Scholar
• Freeman HJ, Kim YS, Sleisenger MH. Protein digestion and absorption. Normal mechanisms and protein-energy malnutrition. Am J Med. 1979;67(6):1030–1036.
   PubMed Web of Science ®Google Scholar
• Cai W, Wu J, Hong L, et al. Oxidative injury and hepatocyte apoptosis in total parenteral nutrition-associated liver dysfunction. J Pediatr Surg. 2006 Oct;41(10):1663–1668.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N. Nonalcoholic steatohepatitis, obesity, and celiac disease. Indian J Gastroenterol. 2003;22(4):156.
   PubMedGoogle Scholar
• Van Tongeren IH, Breed WP, Corstens FH. Fatty liver and malabsorption. Folia Med Neerl. 1972;15(4):246–258.
   PubMedGoogle Scholar
• Capron JP, Sevenet F, Quenum C, et al. Massive hepatic steatosis disclosing adult celiac disease: report of a case and review of the literature. Gastroenterol Clin Biol. 1983;7(3):256–260.
   PubMedGoogle Scholar
• Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585–592.
   PubMed Web of Science ®Google Scholar
• Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30:1151–1158.
   PubMed Web of Science ®Google Scholar
• Hardin DS, Leblanc A, Marshall G, et al. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab. 2001;281(5):E1022–E1028.
   PubMed Web of Science ®Google Scholar
• Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36(5):417–420.
   PubMed Web of Science ®Google Scholar
• Riegler G, D’Incà R, Sturniolo C, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Scand J Gastroenterol. 1998;33(1):93–98.
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Acute liver failure including acetaminophen overdose. Medical Clinics of North America. 2008;92(4):761–794.
   PubMed Web of Science ®Google Scholar
• Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Seminars in Liver Disease. 2002;22(2):145–156.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661–670.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernandez MC, et al. Drug- induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.
   PubMed Web of Science ®Google Scholar
• Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9(5):261–263.
   PubMedGoogle Scholar
• Yoon EJ, Hu K-Q. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci. 2006;3(2):53–56.
   PubMedGoogle Scholar
• Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15(2):129–136.
   PubMed Web of Science ®Google Scholar
• Kneeman JM. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012 May;5(3):199–207.
   PubMed Web of Science ®Google Scholar
• Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639–644.
   PubMed Web of Science ®Google Scholar
• Bjoro K, Bell H, Hellum KB, et al. Effect of combined interferon‐alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol. 2002;37:226–232.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Tsubota A, et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment‐related factors. J Hepatol. 2002;37:831–836.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):3875–3885.
   Google Scholar
• Machado MV. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011 Sep;26(9):1361–1367.
   PubMed Web of Science ®Google Scholar
• Burkhead JL, Gray LW, Lutsenko S. Systems biology approach to Wilson’s disease. Biometals. 2011 Jun;24(3):455–466.
   PubMed Web of Science ®Google Scholar